Harbour BioMed Reports 2021 Interim Results
CAMBRIDGE, Mass.and SUZHOU, China and ROTTERDAM, Netherlands, Aug. 31, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics, reported its interim...
HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, July 26, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced that the abstract detailing clinical data from its Australian phase I study of next-generation anti-CTLA-4 antibody in patients with advanced solid tumo...
Harbour BioMed Appoints Yingying Chen, PhD, as Chief Financial Officer
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, July 20, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX:02142) announced the appointment of Dr. Yingying Chen as Chief Financial Officer (CFO). Dr. Chen will be responsible for leading the overall management of Finance & Investor Re...
Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis
* Both batoclimab 340 mg and 680 mg treatment groups demonstrated rapid, substantial and persistent clinical improvement over placebo * Favorable safety and tolerability profile with no serious adverse events (SAEs) and no adverse events (AEs) leading to discontinuation * Strong IgG reductio...
Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 17, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient of HBM4003 in patients with advanced non-small cell lung cancer in its open phase I clinical study. This study will eval...
Harbour BioMed and Dana-Farber Cancer Institute Collaborate to Advance Novel Biotherapies for Cancer Treatment
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Harbour BioMed (HKEX: 02142) announced today it has entered into a multi-year, multifaceted research collaboration agreement with Dana-Farber Cancer Institute to co-develop novel biotherapies in cancer t...
Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 11, 2021 /PRNewswire/ -- Harbour BioMed ("HBM", HKEX: 02142) today announced the dosing of the first patient in its part 2 of phase I (phase Ib/IIa) clinical study of its next-generation anti-CTLA-4 antibody, where Australian pati...
Harbour BioMed Presents Novel Antibody for Cancer Immunotherapy at 2021 American Association for Cancer Research Annual Meeting
CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 13, 2021 /PRNewswire/ -- Harbour BioMed ("HBM"; HKEX: 02142.HK), a global clinical-stage biopharmaceutical company, presents its newly discovered fully human anti-B7H7 monoclonal antibody at the American Association for Cancer Rese...
Harbour BioMed Announces Dosing of First Patient in Phase I Clinical Study of its Next-Generation Anti-CTLA-4 Antibody in China
SHANGHAI and SUZHOU, China, March 22, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in its open Phase I clinical study of HBM4003 for Chinese patients suffering from advanced melanoma and other solid tumors (study No. 4003.2). This study w...
Harbour BioMed Announces Dosing of First Patient in Tanfanercept Phase III Clinical Trial
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SHANGHAI and SUZHOU, China, March 12, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142) today announced the dosing of the first patient in the Phase III clinical trial of its new global investigational tumor necrosis factor (TNF) receptor-1 f...
Harbour BioMed Announces NMPA Approval of IND for Combination Therapy of Next Gen Anti-CTLA-4 Antibody for Treatment of NSCLC and Solid Tumors
CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, Feb. 26, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142) today announced that the China National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for HBM4003, the next generati...
Harbour BioMed's Batoclimab (HBM9161) Receives China CDE Breakthrough Therapy Designation for Treatment of Adult Patients with Myasthenia Gravis
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Jan. 28, 2021 /PRNewswire/ -- Harbour BioMed (HBM) (HKEX: 02142.HK), announced today that China Center for Drug Evaluation (CDE) has granted Breakthrough Therapy designation to Batoclimab (HBM 9161), a fully human anti-FcRn monoclonal a...
Harbour BioMed Completes Its Global Offering and Listing on the Hong Kong Stock Exchange
CAMBRIDGE, Mass. and SUZHOU, China, Dec. 17, 2020 /PRNewswire/ -- HBM Holdings Limited ("Harbour BioMed", "HBM" or the "Company"; Stock Code: 02142.HK), a global clinical-stage biopharmaceutical company, completed its global offering (the "Global Offering") and its listing on the Main Board of ...
Harbour BioMed and Utrecht University Announce License Agreement with AbbVie and Initiation of COVID-19 Antibody Clinical Trials
CAMBRIDGE, Mass., SUZHOU, China, UTRECHT, Netherlands, Dec. 15, 2020 /PRNewswire/ -- Harbour BioMed (HBM)(HKEX:02142), andUtrecht University (UU) today announced that they licensed to AbbVie their fully human, SARS-CoV-2 neutralizing antibody, 47D11 and program, for the prevention and treatment o...
HBM Holdings Limited Announces the Offer Price and Allotment Results of the Global Offering
This press release is NOT for release, publication, distribution, directly or indirectly, in or intothe United States (including its territories and possessions, any state ofthe United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. Thi...
